Pancreatic & Biliary Cancer

Quick Answer

For pancreatic ductal adenocarcinoma, contrast-enhanced CT/MRI and EUS remain the primary staging tools; FDG-PET/CT contributes mainly by detecting occult distant metastases before major surgery and characterizing indeterminate lesions, though the desmoplastic, variably-avid stroma limits sensitivity. In cholangiocarcinoma and gallbladder cancer, FDG-PET adds nodal, distant, and peritoneal staging. The stroma-targeted tracer FAPI shows particular promise here, given the intensely desmoplastic, often FDG-low nature of these tumors.

Definition

This group comprises pancreatic ductal adenocarcinoma (PDAC) — the dominant pancreatic malignancy — and the biliary tract cancers: cholangiocarcinoma (intrahepatic, perihilar/Klatskin, and distal) and gallbladder carcinoma. (Pancreatic neuroendocrine tumors are a separate, SSTR-imaged entity — see that page.)

Synonyms

PDAC; pancreatic adenocarcinoma; cholangiocarcinoma (CCA); Klatskin tumor (perihilar CCA); gallbladder cancer; periampullary carcinoma.

Epidemiology

PDAC is highly lethal and rising in incidence, typically presenting late; it is a leading cause of cancer death despite comparatively modest incidence. Cholangiocarcinoma incidence varies geographically (high where liver-fluke infection is endemic). Gallbladder cancer shows marked geographic/sex variation and is associated with gallstones and chronic inflammation.

Etiology & Risk Factors

• PDAC: smoking, chronic pancreatitis, new-onset diabetes, obesity, and hereditary predisposition (BRCA2, PALB2, Lynch, Peutz–Jeghers, familial pancreatic cancer, hereditary pancreatitis).
• Cholangiocarcinoma: primary sclerosing cholangitis, liver flukes (Opisthorchis/Clonorchis), choledochal cysts, hepatolithiasis, chronic HBV/HCV, and cirrhosis (intrahepatic).
• Gallbladder: gallstones, chronic inflammation, "porcelain" gallbladder, and anomalous pancreaticobiliary junction.

Pathophysiology

PDAC is defined by an intensely desmoplastic stroma (dense fibroblasts and matrix) that both limits drug delivery and dilutes tumor-cell FDG signal — while presenting an abundance of fibroblast activation protein (FAP), the FAPI target. Early perineural and vascular invasion and a propensity for occult metastatic spread (liver, peritoneum) explain the poor resectability and the value of catching distant disease before surgery. Biliary cancers share desmoplasia and grow along ducts.

Genetics & Molecular Biology

• PDAC: KRAS (~90%), TP53, CDKN2A, SMAD4; BRCA2/PALB2 (platinum/PARP sensitivity), MSI-high minority (immunotherapy).
• Cholangiocarcinoma (actionable): FGFR2 fusions and IDH1 mutations (intrahepatic), HER2 amplification (extrahepatic/gallbladder), BRAF, MSI-high — several with targeted therapies.

Histopathology

Predominantly ductal adenocarcinoma with dense desmoplastic stroma; graded by differentiation. Precursor lesions include PanIN and IPMN/MCN (pancreas) and biliary intraepithelial neoplasia. Perineural invasion is characteristic.

Clinical Presentation

Painless obstructive jaundice (pancreatic head, distal CCA, periampullary — often with a palpable non-tender gallbladder, Courvoisier sign), weight loss, epigastric/back pain, and new-onset diabetes. Intrahepatic CCA presents with a liver mass; perihilar CCA with jaundice and cholangitis. Advanced disease brings ascites (peritoneal spread).

Laboratory Findings

• CA 19-9 — the principal marker (baseline, response, recurrence); false-negative in Lewis-antigen-negative individuals and falsely elevated with cholestasis/cholangitis — interpret against bilirubin.
• Liver function/cholestasis pattern; molecular profiling (KRAS, BRCA, FGFR2, IDH1, HER2, MSI) in advanced disease.

Imaging Findings by Modality

• Pancreatic-protocol (multiphase) CT: the primary tool for resectability (arterial/venous involvement).
• MRI / MRCP: ductal anatomy, liver lesions, and biliary mapping.
• EUS: high-resolution local assessment and tissue biopsy (best for small tumors).
• FDG-PET/CT: detection of occult distant metastases pre-resection and indeterminate-lesion characterization; nodal/distant/peritoneal staging in biliary cancer.
• FAPI-PET (emerging): high tumor-to-background in these desmoplastic, FDG-modest tumors.

Radiopharmaceutical Uptake Mechanisms

FDG reflects tumor-cell glucose metabolism, but the abundant acellular desmoplastic stroma dilutes signal, and hyperglycemia and inflammatory pancreatitis confound it. FAPI binds fibroblast activation protein on cancer-associated fibroblasts — abundant precisely in these stroma-rich tumors — with low physiologic liver/bowel background, an advantage over FDG in the upper abdomen.

Typical PET Tracers

Typical SPECT Tracers

• No routine SPECT role for staging. (⁹⁹ᵐTc-MAA mapping applies if intrahepatic cholangiocarcinoma is considered for Y-90 radioembolization.)

Therapy Indications

• PDAC: surgery (Whipple/distal pancreatectomy) for resectable disease; neoadjuvant and adjuvant chemotherapy (FOLFIRINOX, gemcitabine-based); PARP maintenance (BRCA); MSI-high immunotherapy.
• Cholangiocarcinoma: resection when feasible; gemcitabine–cisplatin (± durvalumab) systemic therapy; targeted agents by molecular class (FGFR2-fusion inhibitors, IDH1 inhibitors, HER2-directed).
• Gallbladder: resection ± adjuvant therapy; systemic therapy for advanced disease.

Theranostics

No established radioligand therapy — but the FAP axis is an active theranostic frontier (FAPI imaging → FAP-targeted radioligand therapy under investigation), attractive precisely because these tumors are stroma-rich and FDG-modest. Currently the nuclear-medicine contribution is staging-defining (catching distant disease that changes surgical candidacy).

Differential Diagnosis

• Chronic and autoimmune (IgG4) pancreatitis — FDG-avid, mimicking malignancy (autoimmune pancreatitis may show diffuse uptake and responds to steroids).
• Pancreatic neuroendocrine tumor (SSTR-avid — image with DOTATATE, not FDG).
• IPMN/mucinous cystic lesions and serous cystadenoma; benign biliary strictures.
• Peritumoral inflammation/obstruction confounding uptake.

Reporting Checklist

• State the indication (occult-metastasis detection / indeterminate lesion / biliary staging) and correlate with CA 19-9 and bilirubin.
• Emphasize distant disease that changes surgical candidacy (the highest-value finding).
• Note the desmoplastic FDG-modest caveat and pancreatitis/hyperglycemia confounders.
• Consider FAPI where FDG is low or liver background is high (research context).

Prognosis

PDAC has among the poorest solid-tumor prognoses, driven by late presentation and early spread; resectability and margin/nodal status dominate outcome, with molecular subsets (BRCA) affecting therapy. Cholangiocarcinoma prognosis depends on location and resectability, improved in actionable-mutation subsets. Detecting occult metastatic disease preoperatively spares non-therapeutic surgery.

Board Pearls

For PDAC, CT/MRI and EUS remain the primary staging tools; FDG-PET/CT's best use is catching occult distant metastases before major surgery and characterizing indeterminate lesions. The desmoplastic, variably-avid stroma limits sensitivity, so a modest SUV does not exclude PDAC; in cholangiocarcinoma/gallbladder cancer, FDG adds nodal, distant, and peritoneal staging.

These tumors are intensely desmoplastic and often FDG-modest — exactly where the stroma-targeted FAPI tracer shows high tumor-to-background (and low liver background), a promising (investigational) complement.

Chronic/autoimmune (IgG4) pancreatitis produces FDG uptake mimicking malignancy, and hyperglycemia degrades interpretation — so never exclude PDAC on a modest SUV, and interpret CA 19-9 against bilirubin (elevated with cholestasis, falsely low in Lewis-negative patients). A pancreatic mass that is SSTR-avid on DOTATATE points to a neuroendocrine tumor, not PDAC.

Related Pages

• Tracer: FDG and (emerging) FAPI.
• Related disease: Neuroendocrine tumors (SSTR-avid pancreatic NET contrast); hepatocellular carcinoma (intrahepatic CCA / Y-90 overlap).
• Pitfalls: Pearls, pitfalls & normal variants.

Figure / Diagram Suggestions

• FDG vs FAPI side-by-side over a desmoplastic pancreatic mass (signal dilution vs stromal contrast).
• A resectability/occult-metastasis decision flow ending at FDG-PET before surgery.
• PDAC vs autoimmune pancreatitis vs pancreatic NET discriminator table (FDG vs steroids-response vs DOTATATE).

Common Pitfalls

• Biliary stents, recent ERCP, or cholangitis produce FDG-avid ductal/periductal inflammation that mimics tumor or nodal disease along the biliary tree.
• Small-volume peritoneal carcinomatosis is frequently below PET resolution, so a negative study does not exclude peritoneal spread (an area where FAPI may add sensitivity).
• Post-operative (post-Whipple) inflammatory and anastomotic uptake mimics recurrence — account for timing since surgery.
• Physiologic duodenal, bowel, and pancreatic uptake can obscure a small pancreatic-head lesion — correlate carefully with contrast CT/MRCP.

Self-Check (Board-Style)